|
| 37921600 | Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution. | J Gynecol Oncol | 2024 |
| 36922497 | Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. | Nat Commun | 2023 |
| 37669480 | Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. | J Clin Oncol | 2023 |
| 37483495 | Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory. | Front Oncol | 2023 |
| 37542936 | Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. | Eur J Cancer | 2023 |
| 36950270 | A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer. | Ther Adv Med Oncol | 2023 |
| 36972022 | Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. | N Engl J Med | 2023 |
| 37334673 | ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. | Future Oncol | 2023 |
| 36319973 | The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis. | BMC Cancer | 2022 |
| 35733492 | An Electronic Information Kiosk for Enhancing Patient Accrual for Cancer Clinical Trials: A Pilot and Feasibility Study. | Cureus | 2022 |
| 36636049 | A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. | J Gastrointest Oncol | 2022 |
| 36028483 | The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. | Nat Commun | 2022 |
| 36055813 | Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma. | Gynecol Oncol | 2022 |
| 34203593 | Abstracts of the 2021 Canadian Association of Medical Oncologists Annual Meeting. | Curr Oncol | 2021 |
| 33485453 | Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. | Lancet | 2021 |
| 33620159 | Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. | Clin Transl Sci | 2021 |
| 34820133 | A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol. | Can J Kidney Health Dis | 2021 |
| 34602290 | Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. | Gynecol Oncol | 2021 |
| 34677260 | The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis. | Curr Oncol | 2021 |
| 33941784 | Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). | Nat Commun | 2021 |
| 34073199 | Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019. | Curr Oncol | 2021 |
| 32632513 | Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. | Breast Cancer Res Treat | 2020 |
| 31724340 | Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. | Cancer Med | 2020 |
| 31992589 | Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). | Clin Cancer Res | 2020 |
| 31922558 | Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis. | JAMA Netw Open | 2020 |
| 31052357 | <i>DPYD</i> and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. | Pharmaceutics | 2019 |
| 31708660 | Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. | Curr Oncol | 2019 |
| 31708655 | OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing. | Curr Oncol | 2019 |
| 31061661 | Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The "Opt-Out" Process. | J Oncol | 2019 |
| 30732962 | Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. | Oral Oncol | 2019 |
| 29145543 | Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. | JAMA Oncol | 2018 |
| 30094551 | Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. | Breast Cancer Res Treat | 2018 |
| 29955792 | Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. | JAMA Oncol | 2018 |
| 30111967 | Eastern Canadian Colorectal Cancer Consensus Conference 2017. | Curr Oncol | 2018 |
| 30108107 | A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. | Clin Cancer Res | 2018 |
| 30390943 | Treatment Tolerance and Side Effects of Intraperitoneal Carboplatin and Dose-Dense Intravenous Paclitaxel in Ovarian Cancer. | J Obstet Gynaecol Can | 2018 |
| 29728308 | Health related quality of life in older or frail patients with advanced colorectal cancer treated with dose reduced capecitabine. | J Geriatr Oncol | 2018 |
| 29653857 | A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. | Clin Colorectal Cancer | 2018 |
| 28062115 | Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). | Gynecol Oncol | 2017 |
| 28464908 | A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. | Breast Cancer Res | 2017 |
| 28389981 | Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. | Invest New Drugs | 2017 |
| 28150073 | First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. | Invest New Drugs | 2017 |
| 28874896 | Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. | Curr Oncol | 2017 |
| 28652999 | Management of colorectal cancer with synchronous liver metastases: impact of multidisciplinary case conference review. | Hepatobiliary Surg Nutr | 2017 |
| 28045335 | Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer. | Future Oncol | 2017 |
| 27993794 | Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. | Ann Oncol | 2017 |
| 25611302 | OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. | Br J Cancer | 2015 |
| 25908913 | Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. | Curr Oncol | 2015 |
| 25908912 | Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. | Curr Oncol | 2015 |
| 25769658 | A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. | Gynecol Oncol | 2015 |